CareDx (CDNA) to Post Quarterly Earnings on Thursday

CareDx (NASDAQ:CDNA) will likely be issuing its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect CareDx to announce earnings of $0.22 per share and revenue of $113.8540 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

CareDx (NASDAQ:CDNA) last released its earnings results on Tuesday, April 28th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.11 by $0.23. The business had revenue of $117.70 million during the quarter, compared to analysts’ expectations of $102.03 million. CareDx had a negative return on equity of 2.65% and a negative net margin of 2.01%.The firm’s revenue was up 39.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.09 earnings per share. On average, analysts expect CareDx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CareDx Stock Performance

Shares of CDNA stock opened at $37.78 on Thursday. The company has a market cap of $1.95 billion, a P/E ratio of -236.12 and a beta of 2.43. The stock has a 50 day simple moving average of $26.23 and a two-hundred day simple moving average of $21.69. CareDx has a fifty-two week low of $11.26 and a fifty-two week high of $40.47.

Insider Buying and Selling at CareDx

In other CareDx news, CEO John Walter Hanna, Jr. sold 39,900 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $29.24, for a total transaction of $1,166,676.00. Following the completion of the sale, the chief executive officer owned 661,959 shares in the company, valued at approximately $19,355,681.16. The trade was a 5.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Hannah Valantine sold 12,103 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $23.11, for a total transaction of $279,700.33. Following the transaction, the director owned 36,686 shares in the company, valued at approximately $847,813.46. The trade was a 24.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 78,936 shares of company stock valued at $2,093,708. 2.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On CareDx

Several large investors have recently added to or reduced their stakes in CDNA. State Street Corp increased its holdings in CareDx by 6.7% during the 4th quarter. State Street Corp now owns 2,737,752 shares of the company’s stock worth $51,579,000 after purchasing an additional 171,303 shares in the last quarter. Bamco Inc. NY lifted its holdings in shares of CareDx by 11.2% in the second quarter. Bamco Inc. NY now owns 2,435,657 shares of the company’s stock valued at $47,593,000 after purchasing an additional 245,651 shares in the last quarter. Deerfield Management Company L.P. purchased a new position in shares of CareDx during the third quarter valued at approximately $31,857,000. Dimensional Fund Advisors LP boosted its position in shares of CareDx by 7.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,309,980 shares of the company’s stock valued at $24,681,000 after buying an additional 93,456 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in CareDx by 18.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company’s stock worth $19,703,000 after buying an additional 170,504 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts have recently commented on CDNA shares. Weiss Ratings downgraded shares of CareDx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, July 15th. William Blair upgraded shares of CareDx to a “hold” rating in a research report on Thursday, July 16th. Wall Street Zen raised shares of CareDx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 3rd. BTIG Research raised their price target on shares of CareDx from $28.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Finally, Craig Hallum reaffirmed a “hold” rating and issued a $35.00 price target on shares of CareDx in a research note on Thursday, July 16th. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $33.67.

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non?invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post?transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor?derived cell?free DNA assay used primarily in kidney transplant monitoring.